ID   LYAG_HUMAN              Reviewed;         952 AA.
AC   P10253; Q09GN4; Q14351; Q16302; Q8IWE7;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   03-AUG-2022, entry version 236.
DE   RecName: Full=Lysosomal alpha-glucosidase;
DE            EC=3.2.1.20 {ECO:0000269|PubMed:18429042, ECO:0000269|PubMed:1856189, ECO:0000269|PubMed:29061980, ECO:0000269|PubMed:7717400};
DE   AltName: Full=Acid maltase;
DE   AltName: Full=Aglucosidase alfa;
DE   Contains:
DE     RecName: Full=76 kDa lysosomal alpha-glucosidase;
DE   Contains:
DE     RecName: Full=70 kDa lysosomal alpha-glucosidase;
DE   Flags: Precursor;
GN   Name=GAA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 70-89; 123-145; 204-215;
RP   230-249; 332-345; 349-370; 394-409; 480-513; 520-545; 703-719; 726-731 AND
RP   795-803, AND VARIANTS ARG-199; HIS-223 AND ILE-780.
RC   TISSUE=Placenta, Testis, and Urine;
RX   PubMed=3049072; DOI=10.1002/j.1460-2075.1988.tb02998.x;
RA   Hoefsloot L.H., Hoogeveen-Westerveld M., Kroos M.A., van Beeumen J.,
RA   Reuser A.J.J., Oostra B.A.;
RT   "Primary structure and processing of lysosomal alpha-glucosidase; homology
RT   with the intestinal sucrase-isomaltase complex.";
RL   EMBO J. 7:1697-1704(1988).
RN   [2]
RP   SEQUENCE REVISION.
RA   Reuser A.J.J.;
RL   Submitted (JUN-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-780.
RX   PubMed=2268276; DOI=10.1042/bj2720493;
RA   Hoefsloot L.H., Hoogeveen-Westerveld M., Reuser A.J.J., Oostra B.A.;
RT   "Characterization of the human lysosomal alpha-glucosidase gene.";
RL   Biochem. J. 272:493-497(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-780.
RX   PubMed=2111708; DOI=10.1089/dna.1990.9.85;
RA   Martiniuk F., Mehler M., Tzall S., Meredith G., Hirschhorn R.;
RT   "Sequence of the cDNA and 5'-flanking region for human acid alpha-
RT   glucosidase, detection of an intron in the 5' untranslated leader sequence,
RT   definition of 18-bp polymorphisms, and differences with previous cDNA and
RT   amino acid sequences.";
RL   DNA Cell Biol. 9:85-94(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANT GSD2 LEU-457, AND VARIANTS ARG-199;
RP   HIS-223 AND ILE-780.
RA   Ghaffari S.R., Sabokbar T., Tahmasebi S., Dastan J.;
RT   "Identification of a novel mutation in the acid alpha glucosidase gene
RT   causing juvenile form of Pompe disease in Iranian population.";
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 631-680, AND VARIANT GSD2 HIS-645.
RX   PubMed=7695647; DOI=10.1006/bbrc.1995.1418;
RA   Lin C.-Y., Shieh J.-J.;
RT   "Identification of a de novo point mutation resulting in infantile form of
RT   Pompe's disease.";
RL   Biochem. Biophys. Res. Commun. 208:886-893(1995).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF TRP-516 AND ASP-518, AND
RP   ACTIVE SITE.
RX   PubMed=1856189; DOI=10.1016/s0021-9258(18)92727-4;
RA   Hermans M.M.P., Kroos M.A., van Beeumen J., Oostra B.A., Reuser A.J.J.;
RT   "Human lysosomal alpha-glucosidase. Characterization of the catalytic
RT   site.";
RL   J. Biol. Chem. 266:13507-13512(1991).
RN   [10]
RP   GLYCOSYLATION AT ASN-140; ASN-233; ASN-390; ASN-470; ASN-652; ASN-882 AND
RP   ASN-925.
RX   PubMed=8435067; DOI=10.1042/bj2890681;
RA   Hermans M.M.P., Wisselaar H.A., Kroos M.A., Oostra B.A., Reuser A.J.J.;
RT   "Human lysosomal alpha-glucosidase: functional characterization of the
RT   glycosylation sites.";
RL   Biochem. J. 289:681-686(1993).
RN   [11]
RP   GLYCOSYLATION AT ASN-470.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [12]
RP   REVIEW ON VARIANTS.
RX   PubMed=7603530; DOI=10.1002/mus.880181414;
RA   Reuser A.J.J., Kroos M.A., Hermans M.M.P., Bijvoet A.G.A., Verbeet M.P.,
RA   van Diggelen O.P., Kleijer W.J., van der Ploeg A.T.;
RT   "Glycogenosis type II (acid maltase deficiency).";
RL   Muscle Nerve 3:S61-S69(1995).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-390.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [14]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B., Schaefer H.,
RA   Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-140; ASN-470; ASN-882 AND
RP   ASN-925.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [19] {ECO:0007744|PDB:5KZW, ECO:0007744|PDB:5KZX}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 79-952, GLYCOSYLATION AT ASN-140;
RP   ASN-233; ASN-390; ASN-470; ASN-652 AND ASN-882, AND DISULFIDE BONDS.
RA   Deming D.T., Garman S.C.;
RT   "The structure of human GAA: structural basis of Pompe disease.";
RL   Submitted (JUL-2016) to the PDB data bank.
RN   [20] {ECO:0007744|PDB:5NN3, ECO:0007744|PDB:5NN4, ECO:0007744|PDB:5NN5, ECO:0007744|PDB:5NN6, ECO:0007744|PDB:5NN8}
RP   X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 81-952 IN COMPLEXES WITH
RP   SUBSTRATE ANALOGS, FUNCTION, CATALYTIC ACTIVITY, GLYCOSYLATION AT ASN-140;
RP   ASN-233; ASN-390; ASN-470; ASN-652 AND ASN-882, AND DISULFIDE BONDS.
RX   PubMed=29061980; DOI=10.1038/s41467-017-01263-3;
RA   Roig-Zamboni V., Cobucci-Ponzano B., Iacono R., Ferrara M.C., Germany S.,
RA   Bourne Y., Parenti G., Moracci M., Sulzenbacher G.;
RT   "Structure of human lysosomal acid alpha-glucosidase-a guide for the
RT   treatment of Pompe disease.";
RL   Nat. Commun. 8:1111-1111(2017).
RN   [21]
RP   VARIANT ASN-91.
RX   PubMed=2203258;
RA   Martiniuk F., Bodkin M., Tzall S., Hirschhorn R.;
RT   "Identification of the base-pair substitution responsible for a human acid
RT   alpha glucosidase allele with lower 'affinity' for glycogen (GAA 2) and
RT   transient gene expression in deficient cells.";
RL   Am. J. Hum. Genet. 47:440-445(1990).
RN   [22]
RP   VARIANT GSD2 THR-318.
RX   PubMed=1652892;
RA   Zhong N., Martiniuk F., Tzall S., Hirschhorn R.;
RT   "Identification of a missense mutation in one allele of a patient with
RT   Pompe disease, and use of endonuclease digestion of PCR-amplified RNA to
RT   demonstrate lack of mRNA expression from the second allele.";
RL   Am. J. Hum. Genet. 49:635-645(1991).
RN   [23]
RP   VARIANT GSD2 LYS-521.
RX   PubMed=1898413; DOI=10.1016/0006-291x(91)91906-s;
RA   Hermans M.M.P., de Graaff E., Kroos M.A., Wisselaar H.A., Oostra B.A.,
RA   Reuser A.J.J.;
RT   "Identification of a point mutation in the human lysosomal alpha-
RT   glucosidase gene causing infantile glycogenosis type II.";
RL   Biochem. Biophys. Res. Commun. 179:919-926(1991).
RN   [24]
RP   VARIANTS GSD2 ARG-643 AND TRP-725.
RX   PubMed=8401535; DOI=10.1002/humu.1380020406;
RA   Hermans M.M.P., Kroos M.A., de Graaff E., Oostra B.A., Reuser A.J.J.;
RT   "Two mutations affecting the transport and maturation of lysosomal alpha-
RT   glucosidase in an adult case of glycogen storage disease type II.";
RL   Hum. Mutat. 2:268-273(1993).
RN   [25]
RP   VARIANT GSD2 GLU-645, AND VARIANTS ILE-816 AND ILE-927.
RX   PubMed=8094613; DOI=10.1042/bj2890687;
RA   Hermans M.M.P., de Graaff E., Kroos M.A., Wisselaar H.A., Willemsen R.,
RA   Oostra B.A., Reuser A.J.J.;
RT   "The conservative substitution Asp-645-->Glu in lysosomal alpha-glucosidase
RT   affects transport and phosphorylation of the enzyme in an adult patient
RT   with glycogen-storage disease type II.";
RL   Biochem. J. 289:687-693(1993).
RN   [26]
RP   VARIANT GSD2 GLU-645, AND VARIANTS ILE-816 AND ILE-927.
RX   PubMed=1684505; DOI=10.1089/dna.1991.10.681;
RA   Martiniuk F., Mehler M., Bodkin M., Tzall S., Hirschhorn K., Zhong N.,
RA   Hirschhorn R.;
RT   "Identification of a missense mutation in an adult-onset patient with
RT   glycogenosis type II expressing only one allele.";
RL   DNA Cell Biol. 10:681-687(1991).
RN   [27]
RP   VARIANTS ILE-816 AND ILE-927.
RX   PubMed=8486380; DOI=10.1006/geno.1993.1185;
RA   Hermans M.M.P., Svetkey L.P., Oostra B.A., Chen Y.T., Reuser A.J.J.;
RT   "The loss of a polymorphic glycosylation site caused by Thr-927-->Ile is
RT   linked to a second polymorphic Val-816-->Ile substitution in lysosomal
RT   alpha-glucosidase of American blacks.";
RL   Genomics 16:300-301(1993).
RN   [28]
RP   VARIANT GSD2 VAL-519.
RX   PubMed=7866409; DOI=10.1002/humu.1380040410;
RA   Huie M.L., Hirschhorn R., Chen A.S., Martiniuk F., Zhong N.;
RT   "Mutation at the catalytic site (M519V) in glycogen storage disease type II
RT   (Pompe disease).";
RL   Hum. Mutat. 4:291-293(1994).
RN   [29]
RP   VARIANT GSD2 TRP-647.
RX   PubMed=7981676; DOI=10.1093/hmg/3.7.1081;
RA   Huie M.L., Chen A.S., Brooks S.S., Grix A., Hirschhorn R.;
RT   "A de novo 13 nt deletion, a newly identified C647W missense mutation and a
RT   deletion of exon 18 in infantile onset glycogen storage disease type II
RT   (GSDII).";
RL   Hum. Mol. Genet. 3:1081-1087(1994).
RN   [30]
RP   VARIANT GSD2 LEU-545.
RX   PubMed=7881422; DOI=10.1093/hmg/3.12.2213;
RA   Hermans M.M.P., de Graaff E., Kroos M.A., Mohkamsing S., Eussen B.J.,
RA   Joosse M., Willemsen R., Kleijer W.J., Oostra B.A., Reuser A.J.J.;
RT   "The effect of a single base pair deletion (delta T525) and a C1634T
RT   missense mutation (Pro545Leu) on the expression of lysosomal alpha-
RT   glucosidase in patients with glycogen storage disease type II.";
RL   Hum. Mol. Genet. 3:2213-2218(1994).
RN   [31]
RP   VARIANTS GSD2 ARG-299 AND LYS-903 DEL, VARIANTS ARG-199; HIS-223 AND
RP   ILE-780, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=7717400;
RA   Boerkoel C.F., Exelbert R., Nicastri C., Nichols R.C., Miller F.W.,
RA   Plotz P.H., Raben N.;
RT   "Leaky splicing mutation in the acid maltase gene is associated with
RT   delayed onset of glycogenosis type II.";
RL   Am. J. Hum. Genet. 56:887-897(1995).
RN   [32]
RP   VARIANT LYS-689.
RX   PubMed=8912788; DOI=10.1111/j.1469-1809.1996.tb00433.x;
RA   Huie M.L., Menaker M., McAlpine P.J., Hirschhorn R.;
RT   "Identification of an E689K substitution as the molecular basis of the
RT   human acid alpha-glucosidase type 4 allozyme (GAA*4).";
RL   Ann. Hum. Genet. 60:365-368(1996).
RN   [33]
RP   VARIANT GSD2 VAL-529.
RX   PubMed=8834250; DOI=10.1007/bf02267074;
RA   Tsunoda H., Ohshima T., Tohyama J., Sasaki M., Sakuragawa N., Martiniuk F.;
RT   "Acid alpha-glucosidase deficiency: identification and expression of a
RT   missense mutation (S529V) in a Japanese adult phenotype.";
RL   Hum. Genet. 97:496-499(1996).
RN   [34]
RP   VARIANTS GSD2 ASN-645; TRP-647; SER-648; GLN-672 AND TRP-672.
RX   PubMed=9535769; DOI=10.1006/bbrc.1998.8255;
RA   Huie M.L., Tsujino S., Brooks S.S., Engel A., Elias E., Bonthron D.T.,
RA   Bessley C., Shanske S., Dimauro S., Goto Y., Hirschhorn R.;
RT   "Glycogen storage disease type II: identification of four novel missense
RT   mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the
RT   acid alpha-glucosidase locus of patients of differing phenotype.";
RL   Biochem. Biophys. Res. Commun. 244:921-927(1998).
RN   [35]
RP   VARIANT GSD2 ARG-309.
RX   PubMed=9660056; DOI=10.1111/j.1399-0004.1998.tb02749.x;
RA   Kroos M.A., van Leenen D., Verbiest J., Reuser A.J.J., Hermans M.M.P.;
RT   "Glycogen storage disease type II: identification of a dinucleotide
RT   deletion and a common missense mutation in the lysosomal alpha-glucosidase
RT   gene.";
RL   Clin. Genet. 53:379-382(1998).
RN   [36]
RP   VARIANTS GSD2 PRO-566; ARG-643 AND ARG-768, AND VARIANTS ASN-91; ARG-199
RP   AND HIS-223.
RX   PubMed=9521422;
RX   DOI=10.1002/(sici)1098-1004(1998)11:3<209::aid-humu5>3.0.co;2-c;
RA   Hermans M.M.P., Kroos M.A., Smeitink J.A.M., van der Ploeg A.T.,
RA   Kleijer W.J., Reuser A.J.J.;
RT   "Glycogen storage disease type II: genetic and biochemical analysis of
RT   novel mutations in infantile patients from Turkish ancestry.";
RL   Hum. Mutat. 11:209-215(1998).
RN   [37]
RP   VARIANT GSD2 GLY-VAL-PRO-VAL-SER-ASN-925 INS.
RX   PubMed=10206684;
RX   DOI=10.1002/(sici)1098-1004(1998)11:5<413::aid-humu16>3.0.co;2-i;
RA   Beesley C.E., Child A.H., Yacoub M.Y.;
RT   "The identification of five novel mutations in the lysosomal acid alpha-
RT   (1,4) glucosidase gene from patients with glycogen storage disease type
RT   II.";
RL   Hum. Mutat. 11:413-413(1998).
RN   [38]
RP   VARIANTS GSD2 LEU-545 AND TRP-638.
RX   PubMed=10737124; DOI=10.1007/s100480050030;
RA   Vorgerd M., Burwinkel B., Reichmann H., Malin J.-P., Kilimann M.W.;
RT   "Adult-onset glycogen storage disease type II: phenotypic and allelic
RT   heterogeneity in German patients.";
RL   Neurogenetics 1:205-211(1998).
RN   [39]
RP   VARIANT GSD2 ARG-481.
RX   PubMed=10189220;
RX   DOI=10.1002/(sici)1098-1004(1999)13:1<83::aid-humu13>3.0.co;2-2;
RA   Raben N., Lee E., Lee L., Hirschhorn R., Plotz P.H.;
RT   "Novel mutations in African American patients with glycogen storage disease
RT   Type II.";
RL   Hum. Mutat. 13:83-84(1999).
RN   [40]
RP   VARIANTS GSD2, AND VARIANTS.
RX   PubMed=10338092;
RX   DOI=10.1002/(sici)1098-1004(1999)13:5<380::aid-humu6>3.0.co;2-a;
RA   Ko T.-M., Hwu W.-L., Lin Y.-W., Tseng L.-H., Hwa H.-L., Wang T.-R.,
RA   Chuang S.-M.;
RT   "Molecular genetic study of Pompe disease in Chinese patients in Taiwan.";
RL   Hum. Mutat. 13:380-384(1999).
RN   [41]
RP   VARIANTS GSD2 PRO-208; LEU-308; LEU-324; MET-585; 607-GLY--HIS-612 DEL;
RP   ARG-643 AND THR-672.
RX   PubMed=11071489; DOI=10.1212/wnl.55.8.1122;
RA   Laforet P., Nicolino M., Eymard P.B., Puech J.P., Caillaud C., Poenaru L.,
RA   Fardeau M.;
RT   "Juvenile and adult-onset acid maltase deficiency in France: genotype-
RT   phenotype correlation.";
RL   Neurology 55:1122-1128(2000).
RN   [42]
RP   VARIANTS GSD2 ARG-219; LYS-262 AND VAL-408.
RX   PubMed=11738358; DOI=10.1016/s0960-8966(01)00247-4;
RA   Fernandez-Hojas R., Huie M.L., Navarro C., Dominguez C., Roig M.,
RA   Lopez-Coronas D., Teijeira S., Anyane-Yeboa K., Hirschhorn R.;
RT   "Identification of six novel mutations in the acid alpha-glucosidase gene
RT   in three Spanish patients with infantile onset glycogen storage disease
RT   type II (Pompe disease).";
RL   Neuromuscul. Disord. 12:159-166(2002).
RN   [43]
RP   VARIANT GSD2 TRP-224, AND CHARACTERIZATION OF VARIANT GSD2 TRP-224.
RX   PubMed=12923862; DOI=10.1002/ajmg.a.20164;
RA   Pittis M.G., Montalvo A.L., Miocic S., Martini C., Deganuto M.,
RA   Candusso M., Ciana G., Bembi B.;
RT   "Identification of four novel mutations in the alpha glucosidase gene in
RT   five Italian patients with infantile onset glycogen storage disease type
RT   II.";
RL   Am. J. Med. Genet. A 121:225-230(2003).
RN   [44]
RP   VARIANTS GSD2 LEU-361 AND CYS-437.
RX   PubMed=12601120; DOI=10.1212/01.wnl.0000048661.95327.bf;
RA   Lam C.W., Yuen Y.P., Chan K.Y., Tong S.F., Lai C.K., Chow T.C., Lee K.C.,
RA   Chan Y.W., Martiniuk F.;
RT   "Juvenile-onset glycogen storage disease type II with novel mutations in
RT   acid alpha-glucosidase gene.";
RL   Neurology 60:715-717(2003).
RN   [45]
RP   VARIANTS GSD2 TRP-224; CYS-600; ARG-619 AND HIS-660, CHARACTERIZATION OF
RP   VARIANTS GSD2 TRP-224; ARG-619 AND HIS-660, AND CHARACTERIZATION OF VARIANT
RP   SER-576.
RX   PubMed=14643388; DOI=10.1016/s0887-8994(03)00267-4;
RA   Pipo J.R., Feng J.-H., Yamamoto T., Ohsaki Y., Nanba E., Tsujino S.,
RA   Sakuragawa N., Martiniuk F., Ninomiya H., Oka A., Ohno K.;
RT   "New GAA mutations in Japanese patients with GSDII (Pompe disease).";
RL   Pediatr. Neurol. 29:284-287(2003).
RN   [46]
RP   VARIANTS GSD2 GLY-103; ARG-219; ARG-285; CYS-292; ARG-293; PRO-308;
RP   ARG-312; PRO-355; ARG-374; PRO-405; PHE-455; ASP-459 DEL; ARG-478; ARG-481;
RP   THR-519; LEU-545; ARG-549; PRO-552; SER-575; LYS-579; CYS-600; ASP-607 AND
RP   ASP-880, CHARACTERIZATION OF VARIANTS, AND FUNCTION.
RX   PubMed=14695532; DOI=10.1002/humu.10286;
RA   Hermans M.M.P., van Leenen D., Kroos M.A., Beesley C.E.,
RA   Van der Ploeg A.T., Sakuraba H., Wevers R., Kleijer W.J., Michelakakis H.,
RA   Kirk E.P., Fletcher J., Bosshard N., Basel-Vanagaite L., Besley G.,
RA   Reuser A.J.J.;
RT   "Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA)
RT   underscore the genotype-phenotype correlation in glycogen storage disease
RT   type II.";
RL   Hum. Mutat. 23:47-56(2004).
RN   [47]
RP   VARIANTS GSD2 PRO-355 AND CYS-702, AND CHARACTERIZATION OF VARIANTS GSD2
RP   PRO-355 AND CYS-702.
RX   PubMed=14972326; DOI=10.1016/j.ymgme.2003.11.011;
RA   Montalvo A.L.E., Cariati R., Deganuto M., Guerci V., Garcia R., Ciana G.,
RA   Bembi B., Pittis M.G.;
RT   "Glycogenosis type II: identification and expression of three novel
RT   mutations in the acid alpha-glucosidase gene causing the infantile form of
RT   the disease.";
RL   Mol. Genet. Metab. 81:203-208(2004).
RN   [48]
RP   VARIANT GSD2 GLN-901, AND VARIANT ASN-645.
RX   PubMed=15145338; DOI=10.1016/j.nmd.2004.02.012;
RA   Kroos M.A., Kirschner J., Gellerich F.N., Hermans M.M., Van der Ploeg A.T.,
RA   Reuser A.J., Korinthenberg R.;
RT   "A case of childhood Pompe disease demonstrating phenotypic variability of
RT   p.Asp645Asn.";
RL   Neuromuscul. Disord. 14:371-374(2004).
RN   [49]
RP   VARIANTS GSD2 VAL-237 AND ARG-293.
RX   PubMed=15668445; DOI=10.1212/01.wnl.0000149528.95362.20;
RA   Anneser J.M., Pongratz D.E., Podskarbi T., Shin Y.S., Schoser B.G.;
RT   "Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient with
RT   an unusual phenotype.";
RL   Neurology 64:368-370(2005).
RN   [50]
RP   VARIANT GSD2 GLY-330.
RX   PubMed=16782080; DOI=10.1016/j.cca.2006.04.007;
RA   Dou W., Gu X., Fu L., Peng C., Zheng J., Martiniuk F., Sheng H.Z.;
RT   "A novel missense mutation in the acid alpha-glucosidase gene causing the
RT   classic infantile form of Pompe disease.";
RL   Clin. Chim. Acta 374:145-146(2006).
RN   [51]
RP   VARIANT GSD2 GLY-ASN-404.
RX   PubMed=16433701; DOI=10.1111/j.1399-0004.2005.00557.x;
RA   Amartino H., Painceira D., Pomponio R.J., Niizawa G., Sabio Paz V.,
RA   Blanco M., Chamoles N.;
RT   "Two clinical forms of glycogen-storage disease type II in two generations
RT   of the same family.";
RL   Clin. Genet. 69:187-188(2006).
RN   [52]
RP   VARIANTS GSD2 ARG-309; PRO-355; LEU-361; PRO-445; ASN-489; ARG-549;
RP   GLN-612; ARG-643; TRP-672 AND CYS-746.
RX   PubMed=16917947; DOI=10.1002/humu.20374;
RA   Montalvo A.L., Bembi B., Donnarumma M., Filocamo M., Parenti G., Rossi M.,
RA   Merlini L., Buratti E., De Filippi P., Dardis A., Stroppiano M., Ciana G.,
RA   Pittis M.G.;
RT   "Mutation profile of the GAA gene in 40 Italian patients with late onset
RT   glycogen storage disease type II.";
RL   Hum. Mutat. 27:999-1006(2006).
RN   [53]
RP   VARIANTS GSD2 PRO-355; ALA-522 AND VAL-610, AND VARIANT ARG-359.
RX   PubMed=17643989; DOI=10.1016/j.nmd.2007.06.002;
RA   Muller-Felber W., Horvath R., Gempel K., Podskarbi T., Shin Y.,
RA   Pongratz D., Walter M.C., Baethmann M., Schlotter-Weigel B., Lochmuller H.,
RA   Schoser B.;
RT   "Late onset Pompe disease: clinical and neurophysiological spectrum of 38
RT   patients including long-term follow-up in 18 patients.";
RL   Neuromuscul. Disord. 17:698-706(2007).
RN   [54]
RP   VARIANTS GSD2 HIS-190; SER-285; PHE-291; PRO-291; LYS-318; ARG-335;
RP   ARG-347; ARG-482; VAL-483; GLN-521; SER-522; LYS-570; GLN-572; PRO-594;
RP   LYS-614; ASN-737; SER-746 AND PRO-935, AND VARIANT LYS-585.
RX   PubMed=18425781; DOI=10.1002/humu.20745;
RA   Kroos M., Pomponio R.J., van Vliet L., Palmer R.E., Phipps M.,
RA   Van der Helm R., Halley D., Reuser A.;
RT   "Update of the Pompe disease mutation database with 107 sequence variants
RT   and a format for severity rating.";
RL   Hum. Mutat. 29:E13-E26(2008).
RN   [55]
RP   VARIANTS GSD2 GLY-103; CYS-191; ARG-219; TRP-224; LYS-262; ARG-293;
RP   PRO-355; LEU-375; ARG-401; ASN-489; ALA-522; PRO-552; TYR-599; TRP-638;
RP   ARG-643 AND ASN-645, CHARACTERIZATION OF VARIANTS GSD2 CYS-191; LEU-375;
RP   ARG-401; ALA-522 AND TYR-599, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=18429042; DOI=10.1002/humu.20753;
RA   Pittis M.G., Donnarumma M., Montalvo A.L.E., Dominissini S., Kroos M.,
RA   Rosano C., Stroppiano M., Bianco M.G., Donati M.A., Parenti G., D'Amico A.,
RA   Ciana G., Di Rocco M., Reuser A., Bembi B., Filocamo M.;
RT   "Molecular and functional characterization of eight novel GAA mutations in
RT   Italian infants with Pompe disease.";
RL   Hum. Mutat. 29:E27-E36(2008).
RN   [56]
RP   VARIANTS GSD2 PRO-46; LEU-217; PRO-486; PRO-594; TYR-612; LYS-635 AND
RP   VAL-638.
RX   PubMed=19588081; DOI=10.1007/s00415-009-5219-y;
RA   Oba-Shinjo S.M., da Silva R., Andrade F.G., Palmer R.E., Pomponio R.J.,
RA   Ciociola K.M., Carvalho S.M., Gutierrez P.S., Porta G., Marrone C.D.,
RA   Munoz V., Grzesiuk A.K., Llerena J.C. Jr., Berditchevsky C.R., Sobreira C.,
RA   Horovitz D., Hatem T.P., Frota E.R., Pecchini R., Kouyoumdjian J.A.,
RA   Werneck L., Amado V.M., Camelo J.S. Jr., Mattaliano R.J., Marie S.K.;
RT   "Pompe disease in a Brazilian series: clinical and molecular analyses with
RT   identification of nine new mutations.";
RL   J. Neurol. 256:1881-1890(2009).
RN   [57]
RP   VARIANT GSD2 SER-558.
RX   PubMed=20350966; DOI=10.1177/0883073809356035;
RA   Alcantara-Ortigoza M.A., Gonzalez-del Angel A., Barrientos-Rios R.,
RA   Cupples C., Garrido-Garcia L.M., de Leon-Bojorge B., Alva-Chaire Adel C.;
RT   "Screening of late-onset Pompe disease in a sample of Mexican patients with
RT   myopathies of unknown etiology: identification of a novel mutation in the
RT   acid alpha-glucosidase gene.";
RL   J. Child Neurol. 25:1034-1037(2010).
RN   [58]
RP   VARIANTS GSD2 PRO-224; LEU-251; LEU-254; LYS-262; SER-266; PRO-291;
RP   VAL-408; ARG-478; TYR-525; LEU-545; PHE-557; ARG-615; GLU-645; GLY-746 AND
RP   CYS-746, AND VARIANTS ALA-271 AND ARG-711.
RX   PubMed=20080426; DOI=10.1016/j.ymgme.2009.12.014;
RA   Labrousse P., Chien Y.H., Pomponio R.J., Keutzer J., Lee N.C., Akmaev V.R.,
RA   Scholl T., Hwu W.L.;
RT   "Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn
RT   screening pilot program.";
RL   Mol. Genet. Metab. 99:379-383(2010).
RN   [59]
RP   VARIANT GSD2 GLY-103, AND VARIANT ASN-91.
RX   PubMed=21109266; DOI=10.1016/j.jns.2010.10.031;
RA   Fidzianska A., Lugowska A., Tylki-Szymanska A.;
RT   "Late form of Pompe disease with glycogen storage in peripheral nerves
RT   axons.";
RL   J. Neurol. Sci. 301:59-62(2011).
RN   [60]
RP   VARIANTS HIS-74; HIS-89; LEU-220; MET-222; ASP-290; GLY-310; VAL-391;
RP   CYS-458; ASP-611; LEU-629; 700-THR-LEU-701 DEL AND ILE-718, AND VARIANTS
RP   GSD2 ARG-103; GLY-108; PHE-127; GLN-224; ARG-234; LYS-234; ILE-316;
RP   GLU-335; LEU-361; LEU-397; VAL-419; HIS-457; TYR-523; SER-558; CYS-575;
RP   ARG-576; HIS-594; LEU-601; ALA-602; PRO-627; ASP-648; LEU-702; LYS-743;
RP   PRO-819 AND PHE-916.
RX   PubMed=22644586; DOI=10.1002/humu.22108;
RA   Kroos M., Hoogeveen-Westerveld M., Michelakakis H., Pomponio R.,
RA   Van der Ploeg A., Halley D., Reuser A., Augoustides-Savvopoulou P.,
RA   Ausems M., Llona J.B., Bautista Lorite J., van der Beek N., Bonafe L.,
RA   Cuk M., D'Hooghe M., Engelen B., Farouk A., Fumic K., Garcia-Delgado E.,
RA   Herzog A., Hurst J., Jones S., Kariminejad M.H., Kucukcongar A.,
RA   Lissens W., Lund A., Majoor-Krakauer D., Kumamoto S., Maravi E., Marie S.,
RA   Mengel E., Mavridou I., Munteis Olivas E., Najmabadi H., Okumiya T.,
RA   Peric S., Paschke E., Plecko B., Robberecht W., Serdaroglu P., Shboul M.,
RA   Tansek M.Z., Tarnutzer A., Stojanovic V.R., Tylki-Szymanska A.,
RA   Venancio M., Verhoeven K.;
RT   "Update of the pompe disease mutation database with 60 novel GAA sequence
RT   variants and additional studies on the functional effect of 34 previously
RT   reported variants.";
RL   Hum. Mutat. 33:1161-1165(2012).
RN   [61]
RP   VARIANTS GSD2 LYS-234; 431-LEU--GLN-433 DEL; LEU-568; LEU-601; CYS-766 AND
RP   ARG-913.
RX   PubMed=22676651; DOI=10.1186/1750-1172-7-35;
RA   Herzog A., Hartung R., Reuser A.J., Hermanns P., Runz H., Karabul N.,
RA   Goekce S., Pohlenz J., Kampmann C., Lampe C., Beck M., Mengel E.;
RT   "A cross-sectional single-centre study on the spectrum of Pompe disease,
RT   German patients: molecular analysis of the GAA gene, manifestation and
RT   genotype-phenotype correlations.";
RL   Orphanet J. Rare Dis. 7:35-35(2012).
RN   [62]
RP   VARIANTS GSD2 VAL-391; HIS-437; PRO-552; ASP-611; VAL-641; TRP-647 AND
RP   PRO-705, AND VARIANTS ASN-91; ARG-199; HIS-223; SER-576; LYS-689; ILE-780
RP   AND ILE-816.
RX   PubMed=25681614; DOI=10.1016/j.gene.2015.02.023;
RA   Turaca L.T., de Faria D.O., Kyosen S.O., Teixeira V.D., Motta F.L.,
RA   Pessoa J.G., Rodrigues E Silva M., de Almeida S.S., D'Almeida V.,
RA   Munoz Rojas M.V., Martins A.M., Pesquero J.B.;
RT   "Novel GAA mutations in patients with Pompe disease.";
RL   Gene 561:124-131(2015).
CC   -!- FUNCTION: Essential for the degradation of glycogen in lysosomes
CC       (PubMed:1856189, PubMed:7717400, PubMed:14695532, PubMed:18429042). Has
CC       highest activity on alpha-1,4-linked glycosidic linkages, but can also
CC       hydrolyze alpha-1,6-linked glucans (PubMed:29061980).
CC       {ECO:0000269|PubMed:14695532, ECO:0000269|PubMed:18429042,
CC       ECO:0000269|PubMed:1856189, ECO:0000269|PubMed:29061980,
CC       ECO:0000269|PubMed:7717400}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Hydrolysis of terminal, non-reducing (1->4)-linked alpha-D-
CC         glucose residues with release of alpha-D-glucose.; EC=3.2.1.20;
CC         Evidence={ECO:0000269|PubMed:18429042, ECO:0000269|PubMed:1856189,
CC         ECO:0000269|PubMed:29061980, ECO:0000269|PubMed:7717400};
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:17897319}. Lysosome
CC       membrane {ECO:0000269|PubMed:17897319}.
CC   -!- PTM: The different forms of acid glucosidase are obtained by
CC       proteolytic processing. {ECO:0000269|PubMed:3049072}.
CC   -!- PTM: Phosphorylation of mannose residues ensures efficient transport of
CC       the enzyme to the lysosomes via the mannose 6-phosphate receptor.
CC   -!- POLYMORPHISM: There are three common alleles of GAA: GAA*1, GAA*2 and
CC       GAA*4. The sequence shown is that of allele GAA*1, which is the most
CC       common. Alleles GAA*2 and GAA*4 are much rarer.
CC       {ECO:0000269|PubMed:21109266, ECO:0000269|PubMed:2203258,
CC       ECO:0000269|PubMed:25681614, ECO:0000269|PubMed:8912788,
CC       ECO:0000269|PubMed:9521422}.
CC   -!- DISEASE: Glycogen storage disease 2 (GSD2) [MIM:232300]: A metabolic
CC       disorder with a broad clinical spectrum. The severe infantile form, or
CC       Pompe disease, presents at birth with massive accumulation of glycogen
CC       in muscle, heart and liver. Cardiomyopathy and muscular hypotonia are
CC       the cardinal features of this form whose life expectancy is less than
CC       two years. The juvenile and adult forms present as limb-girdle muscular
CC       dystrophy beginning in the lower limbs. Final outcome depends on
CC       respiratory muscle failure. Patients with the adult form can be free of
CC       clinical symptoms for most of their life but finally develop a slowly
CC       progressive myopathy. {ECO:0000269|PubMed:10189220,
CC       ECO:0000269|PubMed:10206684, ECO:0000269|PubMed:10338092,
CC       ECO:0000269|PubMed:10737124, ECO:0000269|PubMed:11071489,
CC       ECO:0000269|PubMed:11738358, ECO:0000269|PubMed:12601120,
CC       ECO:0000269|PubMed:12923862, ECO:0000269|PubMed:14643388,
CC       ECO:0000269|PubMed:14695532, ECO:0000269|PubMed:14972326,
CC       ECO:0000269|PubMed:15145338, ECO:0000269|PubMed:15668445,
CC       ECO:0000269|PubMed:16433701, ECO:0000269|PubMed:1652892,
CC       ECO:0000269|PubMed:16782080, ECO:0000269|PubMed:1684505,
CC       ECO:0000269|PubMed:16917947, ECO:0000269|PubMed:17643989,
CC       ECO:0000269|PubMed:18425781, ECO:0000269|PubMed:18429042,
CC       ECO:0000269|PubMed:1898413, ECO:0000269|PubMed:19588081,
CC       ECO:0000269|PubMed:20080426, ECO:0000269|PubMed:20350966,
CC       ECO:0000269|PubMed:21109266, ECO:0000269|PubMed:22644586,
CC       ECO:0000269|PubMed:22676651, ECO:0000269|PubMed:25681614,
CC       ECO:0000269|PubMed:7695647, ECO:0000269|PubMed:7717400,
CC       ECO:0000269|PubMed:7866409, ECO:0000269|PubMed:7881422,
CC       ECO:0000269|PubMed:7981676, ECO:0000269|PubMed:8094613,
CC       ECO:0000269|PubMed:8401535, ECO:0000269|PubMed:8834250,
CC       ECO:0000269|PubMed:9521422, ECO:0000269|PubMed:9535769,
CC       ECO:0000269|PubMed:9660056, ECO:0000269|Ref.5}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 31 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=GAA; Note=Mutations in alpha-glucosidase;
CC       URL="https://medlineplus.gov/genetics/gene/gaa/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-glucosidase entry;
CC       URL="https://en.wikipedia.org/wiki/Alpha-glucosidase";
CC   -!- WEB RESOURCE: Name=Glucosidase, alpha, acid (Pompe disease) (GAA);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/GAA";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y00839; CAA68763.1; -; mRNA.
DR   EMBL; Y00839; CAA68764.1; -; mRNA.
DR   EMBL; X55080; CAC12967.1; -; Genomic_DNA.
DR   EMBL; X55081; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55095; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55082; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55084; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55083; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55098; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55085; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55086; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55087; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55088; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55089; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55090; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55096; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55091; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55092; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55093; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55094; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; X55097; CAC12967.1; JOINED; Genomic_DNA.
DR   EMBL; M34424; AAA52506.1; -; mRNA.
DR   EMBL; DQ907243; ABI53718.1; -; mRNA.
DR   EMBL; AC087741; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC040431; AAH40431.1; -; mRNA.
DR   EMBL; S76893; AAB33842.1; -; mRNA.
DR   CCDS; CCDS32760.1; -.
DR   PIR; A40577; A32609.
DR   RefSeq; NP_000143.2; NM_000152.4.
DR   RefSeq; NP_001073271.1; NM_001079803.2.
DR   RefSeq; NP_001073272.1; NM_001079804.2.
DR   RefSeq; XP_005257250.1; XM_005257193.2.
DR   RefSeq; XP_005257251.1; XM_005257194.4.
DR   PDB; 5KZW; X-ray; 2.00 A; A=79-952.
DR   PDB; 5KZX; X-ray; 2.00 A; A=79-952.
DR   PDB; 5NN3; X-ray; 1.90 A; A=81-952.
DR   PDB; 5NN4; X-ray; 1.83 A; A=81-952.
DR   PDB; 5NN5; X-ray; 2.00 A; A=81-952.
DR   PDB; 5NN6; X-ray; 2.00 A; A=81-952.
DR   PDB; 5NN8; X-ray; 2.45 A; A=81-952.
DR   PDBsum; 5KZW; -.
DR   PDBsum; 5KZX; -.
DR   PDBsum; 5NN3; -.
DR   PDBsum; 5NN4; -.
DR   PDBsum; 5NN5; -.
DR   PDBsum; 5NN6; -.
DR   PDBsum; 5NN8; -.
DR   AlphaFoldDB; P10253; -.
DR   SMR; P10253; -.
DR   BioGRID; 108823; 126.
DR   IntAct; P10253; 30.
DR   MINT; P10253; -.
DR   STRING; 9606.ENSP00000305692; -.
DR   BindingDB; P10253; -.
DR   ChEMBL; CHEMBL2608; -.
DR   DrugBank; DB00284; Acarbose.
DR   DrugBank; DB05200; AT2220.
DR   DrugBank; DB00491; Miglitol.
DR   DrugBank; DB14962; Trastuzumab deruxtecan.
DR   DrugCentral; P10253; -.
DR   GuidetoPHARMACOLOGY; 2611; -.
DR   Allergome; 9614; Hom s Glucosidase.
DR   CAZy; GH31; Glycoside Hydrolase Family 31.
DR   GlyConnect; 723; 17 N-Linked glycans (7 sites).
DR   GlyGen; P10253; 11 sites, 28 N-linked glycans (7 sites), 1 O-linked glycan (3 sites).
DR   iPTMnet; P10253; -.
DR   MetOSite; P10253; -.
DR   PhosphoSitePlus; P10253; -.
DR   BioMuta; GAA; -.
DR   DMDM; 317373572; -.
DR   CPTAC; CPTAC-2224; -.
DR   EPD; P10253; -.
DR   jPOST; P10253; -.
DR   MassIVE; P10253; -.
DR   MaxQB; P10253; -.
DR   PaxDb; P10253; -.
DR   PeptideAtlas; P10253; -.
DR   PRIDE; P10253; -.
DR   ProteomicsDB; 52587; -.
DR   Antibodypedia; 32676; 337 antibodies from 33 providers.
DR   DNASU; 2548; -.
DR   Ensembl; ENST00000302262.8; ENSP00000305692.3; ENSG00000171298.13.
DR   Ensembl; ENST00000390015.7; ENSP00000374665.3; ENSG00000171298.13.
DR   GeneID; 2548; -.
DR   KEGG; hsa:2548; -.
DR   MANE-Select; ENST00000302262.8; ENSP00000305692.3; NM_000152.5; NP_000143.2.
DR   UCSC; uc002jxo.4; human.
DR   CTD; 2548; -.
DR   DisGeNET; 2548; -.
DR   GeneCards; GAA; -.
DR   GeneReviews; GAA; -.
DR   HGNC; HGNC:4065; GAA.
DR   HPA; ENSG00000171298; Low tissue specificity.
DR   MalaCards; GAA; -.
DR   MIM; 232300; phenotype.
DR   MIM; 606800; gene.
DR   neXtProt; NX_P10253; -.
DR   OpenTargets; ENSG00000171298; -.
DR   Orphanet; 308552; Glycogen storage disease due to acid maltase deficiency, infantile onset.
DR   Orphanet; 420429; Glycogen storage disease due to acid maltase deficiency, late-onset.
DR   PharmGKB; PA28476; -.
DR   VEuPathDB; HostDB:ENSG00000171298; -.
DR   eggNOG; KOG1065; Eukaryota.
DR   GeneTree; ENSGT00940000159355; -.
DR   HOGENOM; CLU_000631_11_2_1; -.
DR   InParanoid; P10253; -.
DR   OMA; YDTYTRG; -.
DR   OrthoDB; 151244at2759; -.
DR   PhylomeDB; P10253; -.
DR   TreeFam; TF314577; -.
DR   BRENDA; 3.2.1.20; 2681.
DR   PathwayCommons; P10253; -.
DR   Reactome; R-HSA-5357609; Glycogen storage disease type II (GAA).
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-70221; Glycogen breakdown (glycogenolysis).
DR   SignaLink; P10253; -.
DR   BioGRID-ORCS; 2548; 12 hits in 1069 CRISPR screens.
DR   ChiTaRS; GAA; human.
DR   GeneWiki; Acid_alpha-glucosidase; -.
DR   GenomeRNAi; 2548; -.
DR   Pharos; P10253; Tclin.
DR   PRO; PR:P10253; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P10253; protein.
DR   Bgee; ENSG00000171298; Expressed in granulocyte and 175 other tissues.
DR   ExpressionAtlas; P10253; baseline and differential.
DR   Genevisible; P10253; HS.
DR   GO; GO:0120282; C:autolysosome lumen; IEA:Ensembl.
DR   GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; HDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0004558; F:alpha-1,4-glucosidase activity; IDA:UniProtKB.
DR   GO; GO:0090599; F:alpha-glucosidase activity; EXP:Reactome.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:InterPro.
DR   GO; GO:0004553; F:hydrolase activity, hydrolyzing O-glycosyl compounds; IBA:GO_Central.
DR   GO; GO:0032450; F:maltose alpha-glucosidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0002086; P:diaphragm contraction; IMP:BHF-UCL.
DR   GO; GO:0006006; P:glucose metabolic process; IC:BHF-UCL.
DR   GO; GO:0005980; P:glycogen catabolic process; IDA:UniProtKB.
DR   GO; GO:0061723; P:glycophagy; IEA:Ensembl.
DR   GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007040; P:lysosome organization; IMP:BHF-UCL.
DR   GO; GO:0000023; P:maltose metabolic process; IC:BHF-UCL.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0050884; P:neuromuscular process controlling posture; IEA:Ensembl.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; IEA:Ensembl.
DR   GO; GO:0005985; P:sucrose metabolic process; IC:BHF-UCL.
DR   GO; GO:0009888; P:tissue development; IEA:Ensembl.
DR   GO; GO:0043181; P:vacuolar sequestering; IMP:BHF-UCL.
DR   CDD; cd00111; Trefoil; 1.
DR   Gene3D; 2.60.40.1180; -; 2.
DR   Gene3D; 4.10.110.10; -; 1.
DR   InterPro; IPR031727; Gal_mutarotase_N.
DR   InterPro; IPR011013; Gal_mutarotase_sf_dom.
DR   InterPro; IPR000322; Glyco_hydro_31.
DR   InterPro; IPR030458; Glyco_hydro_31_AS.
DR   InterPro; IPR030459; Glyco_hydro_31_CS.
DR   InterPro; IPR025887; Glyco_hydro_31_N_dom.
DR   InterPro; IPR013780; Glyco_hydro_b.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR017957; P_trefoil_CS.
DR   InterPro; IPR000519; P_trefoil_dom.
DR   InterPro; IPR044913; P_trefoil_dom_sf.
DR   Pfam; PF13802; Gal_mutarotas_2; 1.
DR   Pfam; PF01055; Glyco_hydro_31; 1.
DR   Pfam; PF16863; NtCtMGAM_N; 1.
DR   Pfam; PF00088; Trefoil; 1.
DR   SMART; SM00018; PD; 1.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   SUPFAM; SSF57492; SSF57492; 1.
DR   SUPFAM; SSF74650; SSF74650; 1.
DR   PROSITE; PS00129; GLYCOSYL_HYDROL_F31_1; 1.
DR   PROSITE; PS00707; GLYCOSYL_HYDROL_F31_2; 1.
DR   PROSITE; PS00025; P_TREFOIL_1; 1.
DR   PROSITE; PS51448; P_TREFOIL_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; Disease variant; Disulfide bond;
KW   Glycogen storage disease; Glycoprotein; Glycosidase; Hydrolase; Lysosome;
KW   Membrane; Phosphoprotein; Reference proteome; Signal.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000255"
FT   PROPEP          28..69
FT                   /evidence="ECO:0000269|PubMed:3049072"
FT                   /id="PRO_0000018565"
FT   CHAIN           70..952
FT                   /note="Lysosomal alpha-glucosidase"
FT                   /id="PRO_0000018566"
FT   CHAIN           123..952
FT                   /note="76 kDa lysosomal alpha-glucosidase"
FT                   /id="PRO_0000018567"
FT   CHAIN           204..952
FT                   /note="70 kDa lysosomal alpha-glucosidase"
FT                   /id="PRO_0000018568"
FT   DOMAIN          80..131
FT                   /note="P-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00779"
FT   REGION          47..82
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        518
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10066,
FT                   ECO:0000269|PubMed:1856189, ECO:0000305|PubMed:29061980"
FT   ACT_SITE        521
FT                   /evidence="ECO:0000250"
FT   BINDING         404
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000305|PubMed:29061980"
FT   BINDING         600
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000305|PubMed:29061980"
FT   BINDING         616
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000305|PubMed:29061980"
FT   BINDING         674
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000305|PubMed:29061980"
FT   CARBOHYD        140
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:29061980, ECO:0000269|PubMed:8435067,
FT                   ECO:0000269|Ref.19, ECO:0007744|PDB:5KZW,
FT                   ECO:0007744|PDB:5NN3"
FT   CARBOHYD        233
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:29061980,
FT                   ECO:0000269|PubMed:8435067, ECO:0000269|Ref.19,
FT                   ECO:0007744|PDB:5KZW, ECO:0007744|PDB:5NN3"
FT   CARBOHYD        390
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:29061980, ECO:0000269|PubMed:8435067,
FT                   ECO:0000269|Ref.19, ECO:0007744|PDB:5KZW,
FT                   ECO:0007744|PDB:5NN3"
FT   CARBOHYD        470
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:29061980,
FT                   ECO:0000269|PubMed:8435067, ECO:0000269|Ref.19,
FT                   ECO:0007744|PDB:5KZW, ECO:0007744|PDB:5NN3"
FT   CARBOHYD        652
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:29061980,
FT                   ECO:0000269|PubMed:8435067, ECO:0000269|Ref.19,
FT                   ECO:0007744|PDB:5KZW, ECO:0007744|PDB:5NN3"
FT   CARBOHYD        882
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:29061980, ECO:0000269|PubMed:8435067,
FT                   ECO:0000269|Ref.19, ECO:0007744|PDB:5KZW,
FT                   ECO:0007744|PDB:5NN3"
FT   CARBOHYD        925
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:8435067"
FT   DISULFID        82..109
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00779,
FT                   ECO:0000269|PubMed:29061980, ECO:0000269|Ref.19,
FT                   ECO:0007744|PDB:5KZW, ECO:0007744|PDB:5KZX,
FT                   ECO:0007744|PDB:5NN3, ECO:0007744|PDB:5NN4,
FT                   ECO:0007744|PDB:5NN5, ECO:0007744|PDB:5NN6,
FT                   ECO:0007744|PDB:5NN8"
FT   DISULFID        92..108
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00779,
FT                   ECO:0000269|PubMed:29061980, ECO:0000269|Ref.19,
FT                   ECO:0007744|PDB:5KZW, ECO:0007744|PDB:5KZX,
FT                   ECO:0007744|PDB:5NN3, ECO:0007744|PDB:5NN4,
FT                   ECO:0007744|PDB:5NN5, ECO:0007744|PDB:5NN6,
FT                   ECO:0007744|PDB:5NN8"
FT   DISULFID        103..127
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00779,
FT                   ECO:0000269|PubMed:29061980, ECO:0000269|Ref.19,
FT                   ECO:0007744|PDB:5KZW, ECO:0007744|PDB:5KZX,
FT                   ECO:0007744|PDB:5NN3, ECO:0007744|PDB:5NN4,
FT                   ECO:0007744|PDB:5NN5, ECO:0007744|PDB:5NN6,
FT                   ECO:0007744|PDB:5NN8"
FT   DISULFID        533..558
FT                   /evidence="ECO:0000269|PubMed:29061980, ECO:0000269|Ref.19,
FT                   ECO:0007744|PDB:5KZW, ECO:0007744|PDB:5KZX,
FT                   ECO:0007744|PDB:5NN3, ECO:0007744|PDB:5NN4,
FT                   ECO:0007744|PDB:5NN5, ECO:0007744|PDB:5NN6,
FT                   ECO:0007744|PDB:5NN8"
FT   DISULFID        647..658
FT                   /evidence="ECO:0000269|PubMed:29061980, ECO:0000269|Ref.19,
FT                   ECO:0007744|PDB:5KZW, ECO:0007744|PDB:5KZX,
FT                   ECO:0007744|PDB:5NN3, ECO:0007744|PDB:5NN4,
FT                   ECO:0007744|PDB:5NN5, ECO:0007744|PDB:5NN6,
FT                   ECO:0007744|PDB:5NN8"
FT   VARIANT         46
FT                   /note="S -> P (in GSD2; dbSNP:rs777215354)"
FT                   /evidence="ECO:0000269|PubMed:19588081"
FT                   /id="VAR_068564"
FT   VARIANT         74
FT                   /note="R -> H (in dbSNP:rs764797280)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068565"
FT   VARIANT         89
FT                   /note="R -> H (in dbSNP:rs200586324)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068566"
FT   VARIANT         91
FT                   /note="D -> N (in allele GAA*2; lower affinity for glycogen
FT                   and starch but not for lower-molecular weight substrates;
FT                   dbSNP:rs1800299)"
FT                   /evidence="ECO:0000269|PubMed:21109266,
FT                   ECO:0000269|PubMed:2203258, ECO:0000269|PubMed:25681614,
FT                   ECO:0000269|PubMed:9521422"
FT                   /id="VAR_004285"
FT   VARIANT         103
FT                   /note="C -> G (in GSD2; infantile form; severe; loss of
FT                   activity; shows enzyme localization primarily in the
FT                   ER-Golgi compartment suggesting that mutation could affect
FT                   the normal processing and stability of the enzyme;
FT                   dbSNP:rs398123174)"
FT                   /evidence="ECO:0000269|PubMed:14695532,
FT                   ECO:0000269|PubMed:18429042, ECO:0000269|PubMed:21109266"
FT                   /id="VAR_018078"
FT   VARIANT         103
FT                   /note="C -> R (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068567"
FT   VARIANT         108
FT                   /note="C -> G (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068568"
FT   VARIANT         127
FT                   /note="C -> F (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068569"
FT   VARIANT         190
FT                   /note="R -> H (in GSD2; dbSNP:rs528367092)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068570"
FT   VARIANT         191
FT                   /note="Y -> C (in GSD2; extremely low residual enzymatic
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:18429042"
FT                   /id="VAR_046467"
FT   VARIANT         199
FT                   /note="H -> R (in dbSNP:rs1042393)"
FT                   /evidence="ECO:0000269|PubMed:25681614,
FT                   ECO:0000269|PubMed:3049072, ECO:0000269|PubMed:7717400,
FT                   ECO:0000269|PubMed:9521422, ECO:0000269|Ref.5"
FT                   /id="VAR_004286"
FT   VARIANT         208
FT                   /note="L -> P (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:11071489"
FT                   /id="VAR_029025"
FT   VARIANT         217
FT                   /note="P -> L (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:19588081"
FT                   /id="VAR_068571"
FT   VARIANT         219
FT                   /note="G -> R (in GSD2; infantile form; severe; loss of
FT                   activity; dbSNP:rs370950728)"
FT                   /evidence="ECO:0000269|PubMed:11738358,
FT                   ECO:0000269|PubMed:14695532, ECO:0000269|PubMed:18429042"
FT                   /id="VAR_018079"
FT   VARIANT         220
FT                   /note="V -> L (in dbSNP:rs530478036)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068572"
FT   VARIANT         222
FT                   /note="V -> M (in dbSNP:rs374569672)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068573"
FT   VARIANT         223
FT                   /note="R -> H (in dbSNP:rs1042395)"
FT                   /evidence="ECO:0000269|PubMed:25681614,
FT                   ECO:0000269|PubMed:3049072, ECO:0000269|PubMed:7717400,
FT                   ECO:0000269|PubMed:9521422, ECO:0000269|Ref.5"
FT                   /id="VAR_004287"
FT   VARIANT         224
FT                   /note="R -> P (in GSD2; dbSNP:rs200210219)"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068574"
FT   VARIANT         224
FT                   /note="R -> Q (in GSD2; dbSNP:rs200210219)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068575"
FT   VARIANT         224
FT                   /note="R -> W (in GSD2; infantile; mild partial loss of
FT                   activity; dbSNP:rs757700700)"
FT                   /evidence="ECO:0000269|PubMed:12923862,
FT                   ECO:0000269|PubMed:14643388, ECO:0000269|PubMed:18429042"
FT                   /id="VAR_029026"
FT   VARIANT         234
FT                   /note="T -> K (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586,
FT                   ECO:0000269|PubMed:22676651"
FT                   /id="VAR_068576"
FT   VARIANT         234
FT                   /note="T -> R (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068577"
FT   VARIANT         237
FT                   /note="A -> V (in GSD2; dbSNP:rs121907944)"
FT                   /evidence="ECO:0000269|PubMed:15668445"
FT                   /id="VAR_029027"
FT   VARIANT         251
FT                   /note="S -> L (in GSD2; dbSNP:rs200856561)"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068578"
FT   VARIANT         254
FT                   /note="S -> L (in GSD2; dbSNP:rs577915581)"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068579"
FT   VARIANT         262
FT                   /note="E -> K (in GSD2; infantile; severe;
FT                   dbSNP:rs201896815)"
FT                   /evidence="ECO:0000269|PubMed:11738358,
FT                   ECO:0000269|PubMed:18429042, ECO:0000269|PubMed:20080426"
FT                   /id="VAR_029028"
FT   VARIANT         266
FT                   /note="P -> S (in GSD2; dbSNP:rs1555599667)"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068580"
FT   VARIANT         271
FT                   /note="T -> A"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068581"
FT   VARIANT         285
FT                   /note="P -> R (in GSD2; juvenile form; mild; partial loss
FT                   of activity; dbSNP:rs764622267)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018080"
FT   VARIANT         285
FT                   /note="P -> S (in GSD2; dbSNP:rs886042086)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068582"
FT   VARIANT         290
FT                   /note="N -> D (in dbSNP:rs552929702)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068583"
FT   VARIANT         291
FT                   /note="L -> F (in GSD2; dbSNP:rs773417785)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068584"
FT   VARIANT         291
FT                   /note="L -> P (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:18425781,
FT                   ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068585"
FT   VARIANT         292
FT                   /note="Y -> C (in GSD2; juvenile form; mild; partial loss
FT                   of activity; dbSNP:rs1057516600)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018081"
FT   VARIANT         293
FT                   /note="G -> R (in GSD2; infantile form; severe; almost
FT                   complete loss of activity; dbSNP:rs121907945)"
FT                   /evidence="ECO:0000269|PubMed:14695532,
FT                   ECO:0000269|PubMed:15668445, ECO:0000269|PubMed:18429042"
FT                   /id="VAR_018082"
FT   VARIANT         299
FT                   /note="L -> R (in GSD2; infantile form; dbSNP:rs121907940)"
FT                   /evidence="ECO:0000269|PubMed:7717400"
FT                   /id="VAR_004288"
FT   VARIANT         308
FT                   /note="H -> L (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:11071489"
FT                   /id="VAR_046468"
FT   VARIANT         308
FT                   /note="H -> P (in GSD2; infantile form; severe; complete
FT                   loss of activity)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018083"
FT   VARIANT         309
FT                   /note="G -> R (in GSD2; severe; dbSNP:rs543300039)"
FT                   /evidence="ECO:0000269|PubMed:16917947,
FT                   ECO:0000269|PubMed:9660056"
FT                   /id="VAR_018084"
FT   VARIANT         310
FT                   /note="V -> G (found in a patient with GSD2; unknown
FT                   pathological significance; dbSNP:rs763091901)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068586"
FT   VARIANT         312
FT                   /note="L -> R (in GSD2; infantile form; severe; loss of
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018085"
FT   VARIANT         316
FT                   /note="N -> I (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068587"
FT   VARIANT         318
FT                   /note="M -> K (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068588"
FT   VARIANT         318
FT                   /note="M -> T (in GSD2; severe; dbSNP:rs121907936)"
FT                   /evidence="ECO:0000269|PubMed:1652892"
FT                   /id="VAR_004289"
FT   VARIANT         324
FT                   /note="P -> L (in GSD2; dbSNP:rs750030887)"
FT                   /evidence="ECO:0000269|PubMed:11071489"
FT                   /id="VAR_029029"
FT   VARIANT         330
FT                   /note="W -> G (in GSD2; infantile form; severe)"
FT                   /evidence="ECO:0000269|PubMed:16782080"
FT                   /id="VAR_029030"
FT   VARIANT         335
FT                   /note="G -> E (in GSD2; dbSNP:rs730880022)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068589"
FT   VARIANT         335
FT                   /note="G -> R (in GSD2; dbSNP:rs202095215)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068590"
FT   VARIANT         347
FT                   /note="P -> R (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068591"
FT   VARIANT         355
FT                   /note="L -> P (in GSD2; infantile form; severe; loss of
FT                   activity; dbSNP:rs766074609)"
FT                   /evidence="ECO:0000269|PubMed:14695532,
FT                   ECO:0000269|PubMed:14972326, ECO:0000269|PubMed:16917947,
FT                   ECO:0000269|PubMed:17643989, ECO:0000269|PubMed:18429042"
FT                   /id="VAR_018086"
FT   VARIANT         359
FT                   /note="G -> R"
FT                   /evidence="ECO:0000269|PubMed:17643989"
FT                   /id="VAR_068592"
FT   VARIANT         361
FT                   /note="P -> L (in GSD2; juvenile form; severe;
FT                   dbSNP:rs755253527)"
FT                   /evidence="ECO:0000269|PubMed:12601120,
FT                   ECO:0000269|PubMed:16917947, ECO:0000269|PubMed:22644586"
FT                   /id="VAR_029031"
FT   VARIANT         374
FT                   /note="C -> R (in GSD2; infantile form; severe; loss of
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018087"
FT   VARIANT         375
FT                   /note="R -> L (in GSD2; extremely low residual enzymatic
FT                   activity; dbSNP:rs142752477)"
FT                   /evidence="ECO:0000269|PubMed:18429042"
FT                   /id="VAR_046469"
FT   VARIANT         377
FT                   /note="G -> R (in GSD2; severe; dbSNP:rs752002666)"
FT                   /id="VAR_029032"
FT   VARIANT         391
FT                   /note="M -> V (found in a patient with GSD2; unknown
FT                   pathological significance; dbSNP:rs778634337)"
FT                   /evidence="ECO:0000269|PubMed:22644586,
FT                   ECO:0000269|PubMed:25681614"
FT                   /id="VAR_068593"
FT   VARIANT         397
FT                   /note="P -> L (in GSD2; dbSNP:rs776008078)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068594"
FT   VARIANT         401
FT                   /note="Q -> R (in GSD2; extremely low residual enzymatic
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:18429042"
FT                   /id="VAR_046470"
FT   VARIANT         402
FT                   /note="W -> R (in GSD2; severe)"
FT                   /id="VAR_004290"
FT   VARIANT         404
FT                   /note="D -> N (in GSD2; severe; dbSNP:rs141533320)"
FT                   /id="VAR_029033"
FT   VARIANT         405
FT                   /note="L -> P (in GSD2; infantile form; severe; loss of
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018088"
FT   VARIANT         408
FT                   /note="M -> V (in GSD2; juvenile form; severe;
FT                   dbSNP:rs560575383)"
FT                   /evidence="ECO:0000269|PubMed:11738358,
FT                   ECO:0000269|PubMed:20080426"
FT                   /id="VAR_029034"
FT   VARIANT         419
FT                   /note="D -> V (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068595"
FT   VARIANT         431..433
FT                   /note="Missing (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22676651"
FT                   /id="VAR_070017"
FT   VARIANT         437
FT                   /note="R -> C (in GSD2; juvenile form; severe;
FT                   dbSNP:rs770610356)"
FT                   /evidence="ECO:0000269|PubMed:12601120"
FT                   /id="VAR_029035"
FT   VARIANT         437
FT                   /note="R -> H (in GSD2; unknown pathological significance;
FT                   dbSNP:rs150868652)"
FT                   /evidence="ECO:0000269|PubMed:25681614"
FT                   /id="VAR_074277"
FT   VARIANT         445
FT                   /note="A -> P (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:16917947"
FT                   /id="VAR_029036"
FT   VARIANT         455
FT                   /note="Y -> F (in GSD2; juvenile form; almost complete loss
FT                   of activity)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018089"
FT   VARIANT         457
FT                   /note="P -> H (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068596"
FT   VARIANT         457
FT                   /note="P -> L (in GSD2; juvenile form)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_029040"
FT   VARIANT         458
FT                   /note="Y -> C (in dbSNP:rs1358826817)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068597"
FT   VARIANT         459
FT                   /note="Missing (in GSD2; infantile form; severe)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018090"
FT   VARIANT         478
FT                   /note="G -> R (in GSD2; severe; loss of activity;
FT                   dbSNP:rs778068209)"
FT                   /evidence="ECO:0000269|PubMed:14695532,
FT                   ECO:0000269|PubMed:20080426"
FT                   /id="VAR_004291"
FT   VARIANT         481
FT                   /note="W -> R (in GSD2; severe; loss of activity;
FT                   dbSNP:rs772883420)"
FT                   /evidence="ECO:0000269|PubMed:10189220,
FT                   ECO:0000269|PubMed:14695532"
FT                   /id="VAR_004292"
FT   VARIANT         482
FT                   /note="P -> R (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068598"
FT   VARIANT         483
FT                   /note="G -> V (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068599"
FT   VARIANT         486
FT                   /note="A -> P (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:19588081"
FT                   /id="VAR_068600"
FT   VARIANT         489
FT                   /note="D -> N (in GSD2; severe; dbSNP:rs398123169)"
FT                   /evidence="ECO:0000269|PubMed:16917947,
FT                   ECO:0000269|PubMed:18429042"
FT                   /id="VAR_029037"
FT   VARIANT         519
FT                   /note="M -> T (in GSD2; severe; loss of activity;
FT                   dbSNP:rs786204720)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_004293"
FT   VARIANT         519
FT                   /note="M -> V (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:7866409"
FT                   /id="VAR_004294"
FT   VARIANT         521
FT                   /note="E -> K (in GSD2; severe; dbSNP:rs121907937)"
FT                   /evidence="ECO:0000269|PubMed:1898413"
FT                   /id="VAR_004295"
FT   VARIANT         521
FT                   /note="E -> Q (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068601"
FT   VARIANT         522
FT                   /note="P -> A (in GSD2; no residual enzymatic activity;
FT                   dbSNP:rs1057517146)"
FT                   /evidence="ECO:0000269|PubMed:17643989,
FT                   ECO:0000269|PubMed:18429042"
FT                   /id="VAR_046471"
FT   VARIANT         522
FT                   /note="P -> S (in GSD2; dbSNP:rs892129065)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068602"
FT   VARIANT         523
FT                   /note="S -> Y (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068603"
FT   VARIANT         525
FT                   /note="F -> Y (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068604"
FT   VARIANT         529
FT                   /note="S -> V (in GSD2; mild; requires 2 nucleotide
FT                   substitutions; dbSNP:rs121907941)"
FT                   /evidence="ECO:0000269|PubMed:8834250"
FT                   /id="VAR_004296"
FT   VARIANT         545
FT                   /note="P -> L (in GSD2; mild; partial loss of activity;
FT                   dbSNP:rs121907942)"
FT                   /evidence="ECO:0000269|PubMed:10737124,
FT                   ECO:0000269|PubMed:14695532, ECO:0000269|PubMed:20080426,
FT                   ECO:0000269|PubMed:7881422"
FT                   /id="VAR_004297"
FT   VARIANT         549
FT                   /note="G -> R (in GSD2; juvenile form; mild; partial loss
FT                   of activity)"
FT                   /evidence="ECO:0000269|PubMed:14695532,
FT                   ECO:0000269|PubMed:16917947"
FT                   /id="VAR_018091"
FT   VARIANT         552
FT                   /note="L -> P (in GSD2; infantile/juvenile form; severe;
FT                   loss of activity; dbSNP:rs779556619)"
FT                   /evidence="ECO:0000269|PubMed:14695532,
FT                   ECO:0000269|PubMed:18429042, ECO:0000269|PubMed:25681614"
FT                   /id="VAR_018092"
FT   VARIANT         557
FT                   /note="I -> F (in GSD2; dbSNP:rs747150965)"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068605"
FT   VARIANT         558
FT                   /note="C -> S (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:20350966,
FT                   ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068606"
FT   VARIANT         566
FT                   /note="S -> P (in GSD2; infantile form)"
FT                   /evidence="ECO:0000269|PubMed:9521422"
FT                   /id="VAR_004298"
FT   VARIANT         568
FT                   /note="H -> L (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22676651"
FT                   /id="VAR_070018"
FT   VARIANT         570
FT                   /note="N -> K (in GSD2; dbSNP:rs765362308)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068607"
FT   VARIANT         572
FT                   /note="H -> Q (in GSD2; dbSNP:rs772962666)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068608"
FT   VARIANT         575
FT                   /note="Y -> C (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068609"
FT   VARIANT         575
FT                   /note="Y -> S (in GSD2; juvenile form)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018093"
FT   VARIANT         576
FT                   /note="G -> A"
FT                   /id="VAR_004299"
FT   VARIANT         576
FT                   /note="G -> R (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068610"
FT   VARIANT         576
FT                   /note="G -> S (retains about half of the activity compared
FT                   with the wild-type; dbSNP:rs1800307)"
FT                   /evidence="ECO:0000269|PubMed:14643388,
FT                   ECO:0000269|PubMed:25681614"
FT                   /id="VAR_004300"
FT   VARIANT         579
FT                   /note="E -> K (in GSD2; infantile form; severe; loss of
FT                   activity; dbSNP:rs991082382)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018094"
FT   VARIANT         585
FT                   /note="R -> K (in dbSNP:rs747373179)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068611"
FT   VARIANT         585
FT                   /note="R -> M (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:11071489"
FT                   /id="VAR_046472"
FT   VARIANT         594
FT                   /note="R -> H (in GSD2; dbSNP:rs775450536)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068612"
FT   VARIANT         594
FT                   /note="R -> P (in GSD2; dbSNP:rs775450536)"
FT                   /evidence="ECO:0000269|PubMed:18425781,
FT                   ECO:0000269|PubMed:19588081"
FT                   /id="VAR_068613"
FT   VARIANT         599
FT                   /note="S -> Y (in GSD2; no residual enzymatic activity;
FT                   dbSNP:rs753505203)"
FT                   /evidence="ECO:0000269|PubMed:18429042"
FT                   /id="VAR_046473"
FT   VARIANT         600
FT                   /note="R -> C (in GSD2; juvenile form; loss of activity;
FT                   dbSNP:rs764670084)"
FT                   /evidence="ECO:0000269|PubMed:14643388,
FT                   ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018095"
FT   VARIANT         600
FT                   /note="R -> H (in GSD2; infantile form; dbSNP:rs377544304)"
FT                   /id="VAR_008689"
FT   VARIANT         601
FT                   /note="S -> L (in GSD2; dbSNP:rs374470794)"
FT                   /evidence="ECO:0000269|PubMed:22644586,
FT                   ECO:0000269|PubMed:22676651"
FT                   /id="VAR_068614"
FT   VARIANT         602
FT                   /note="T -> A (in GSD2; dbSNP:rs781484283)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068615"
FT   VARIANT         607..612
FT                   /note="Missing (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:11071489"
FT                   /id="VAR_046474"
FT   VARIANT         607
FT                   /note="G -> D (in GSD2; infantile form; severe; loss of
FT                   activity; dbSNP:rs1393386120)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018096"
FT   VARIANT         610
FT                   /note="A -> V (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:17643989"
FT                   /id="VAR_068616"
FT   VARIANT         611
FT                   /note="G -> D (found in a patient with GSD2; unknown
FT                   pathological significance; dbSNP:rs1057517105)"
FT                   /evidence="ECO:0000269|PubMed:22644586,
FT                   ECO:0000269|PubMed:25681614"
FT                   /id="VAR_068617"
FT   VARIANT         612
FT                   /note="H -> Q (in GSD2; dbSNP:rs768397968)"
FT                   /evidence="ECO:0000269|PubMed:16917947"
FT                   /id="VAR_029038"
FT   VARIANT         612
FT                   /note="H -> Y (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:19588081"
FT                   /id="VAR_068618"
FT   VARIANT         614
FT                   /note="T -> K (in GSD2; dbSNP:rs369531647)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068619"
FT   VARIANT         615
FT                   /note="G -> R (in GSD2; infantile/adult form;
FT                   dbSNP:rs549029029)"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_008690"
FT   VARIANT         619
FT                   /note="S -> R (in GSD2; loss of function of the mutant
FT                   enzyme; dbSNP:rs914396317)"
FT                   /evidence="ECO:0000269|PubMed:14643388"
FT                   /id="VAR_046475"
FT   VARIANT         627
FT                   /note="S -> P (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068620"
FT   VARIANT         629
FT                   /note="P -> L (in dbSNP:rs746961289)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068621"
FT   VARIANT         635
FT                   /note="N -> K (in GSD2; dbSNP:rs1414146587)"
FT                   /evidence="ECO:0000269|PubMed:19588081"
FT                   /id="VAR_068622"
FT   VARIANT         638
FT                   /note="G -> V (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:19588081"
FT                   /id="VAR_068623"
FT   VARIANT         638
FT                   /note="G -> W (in GSD2; dbSNP:rs757617999)"
FT                   /evidence="ECO:0000269|PubMed:10737124,
FT                   ECO:0000269|PubMed:18429042"
FT                   /id="VAR_046476"
FT   VARIANT         641
FT                   /note="L -> V (in GSD2; unknown pathological significance;
FT                   dbSNP:rs1420043899)"
FT                   /evidence="ECO:0000269|PubMed:25681614"
FT                   /id="VAR_074278"
FT   VARIANT         643
FT                   /note="G -> R (in GSD2; infantile form; dbSNP:rs28937909)"
FT                   /evidence="ECO:0000269|PubMed:11071489,
FT                   ECO:0000269|PubMed:16917947, ECO:0000269|PubMed:18429042,
FT                   ECO:0000269|PubMed:8401535, ECO:0000269|PubMed:9521422"
FT                   /id="VAR_004301"
FT   VARIANT         645
FT                   /note="D -> E (in GSD2; infantile form; most common
FT                   mutation; deficient in phosphorylation and in proteolytic
FT                   processing; dbSNP:rs28940868)"
FT                   /evidence="ECO:0000269|PubMed:1684505,
FT                   ECO:0000269|PubMed:20080426, ECO:0000269|PubMed:8094613"
FT                   /id="VAR_004302"
FT   VARIANT         645
FT                   /note="D -> H (in GSD2; almost complete loss of activity;
FT                   dbSNP:rs368438393)"
FT                   /evidence="ECO:0000269|PubMed:7695647"
FT                   /id="VAR_004303"
FT   VARIANT         645
FT                   /note="D -> N (in GSD2; dbSNP:rs368438393)"
FT                   /evidence="ECO:0000269|PubMed:15145338,
FT                   ECO:0000269|PubMed:18429042, ECO:0000269|PubMed:9535769"
FT                   /id="VAR_004304"
FT   VARIANT         647
FT                   /note="C -> W (in GSD2; dbSNP:rs776948121)"
FT                   /evidence="ECO:0000269|PubMed:25681614,
FT                   ECO:0000269|PubMed:7981676, ECO:0000269|PubMed:9535769"
FT                   /id="VAR_004305"
FT   VARIANT         648
FT                   /note="G -> D (in GSD2; dbSNP:rs1448515860)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068624"
FT   VARIANT         648
FT                   /note="G -> S (in GSD2; dbSNP:rs536906561)"
FT                   /evidence="ECO:0000269|PubMed:9535769"
FT                   /id="VAR_004306"
FT   VARIANT         660
FT                   /note="R -> H (in GSD2; loss of function of the mutant
FT                   enzyme; dbSNP:rs374143224)"
FT                   /evidence="ECO:0000269|PubMed:14643388"
FT                   /id="VAR_046477"
FT   VARIANT         672
FT                   /note="R -> Q (in GSD2; dbSNP:rs778418246)"
FT                   /evidence="ECO:0000269|PubMed:9535769"
FT                   /id="VAR_004307"
FT   VARIANT         672
FT                   /note="R -> T (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:11071489"
FT                   /id="VAR_046478"
FT   VARIANT         672
FT                   /note="R -> W (in GSD2; dbSNP:rs757111744)"
FT                   /evidence="ECO:0000269|PubMed:16917947,
FT                   ECO:0000269|PubMed:9535769"
FT                   /id="VAR_004308"
FT   VARIANT         675
FT                   /note="Missing (in GSD2; infantile form)"
FT                   /id="VAR_008692"
FT   VARIANT         689
FT                   /note="E -> K (in allele GAA*4; dbSNP:rs1800309)"
FT                   /evidence="ECO:0000269|PubMed:25681614,
FT                   ECO:0000269|PubMed:8912788"
FT                   /id="VAR_004309"
FT   VARIANT         700..701
FT                   /note="Missing (found in a patient with GSD2; unknown
FT                   pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068625"
FT   VARIANT         702
FT                   /note="R -> C (in GSD2; no enzymatic activity; shows enzyme
FT                   localization primarily in the ER-Golgi compartment
FT                   suggesting that mutation could affect the normal processing
FT                   and stability of the enzyme; dbSNP:rs786204645)"
FT                   /evidence="ECO:0000269|PubMed:14972326"
FT                   /id="VAR_046479"
FT   VARIANT         702
FT                   /note="R -> L (in GSD2; dbSNP:rs398123172)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068626"
FT   VARIANT         705
FT                   /note="L -> P (in GSD2; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:25681614"
FT                   /id="VAR_074279"
FT   VARIANT         711
FT                   /note="T -> R (in dbSNP:rs759292700)"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068627"
FT   VARIANT         718
FT                   /note="V -> I (in dbSNP:rs141017311)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068628"
FT   VARIANT         725
FT                   /note="R -> W (in GSD2; adult form; dbSNP:rs121907938)"
FT                   /evidence="ECO:0000269|PubMed:8401535"
FT                   /id="VAR_004310"
FT   VARIANT         737
FT                   /note="T -> N (in GSD2; dbSNP:rs1381005435)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068629"
FT   VARIANT         743
FT                   /note="Q -> K (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068630"
FT   VARIANT         746
FT                   /note="W -> C (in GSD2; dbSNP:rs1800312)"
FT                   /evidence="ECO:0000269|PubMed:16917947,
FT                   ECO:0000269|PubMed:20080426"
FT                   /id="VAR_004311"
FT   VARIANT         746
FT                   /note="W -> G (in GSD2; dbSNP:rs1479740763)"
FT                   /evidence="ECO:0000269|PubMed:20080426"
FT                   /id="VAR_068631"
FT   VARIANT         746
FT                   /note="W -> S (in GSD2; dbSNP:rs752921215)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068632"
FT   VARIANT         766
FT                   /note="Y -> C (in GSD2; dbSNP:rs144016984)"
FT                   /evidence="ECO:0000269|PubMed:22676651"
FT                   /id="VAR_070019"
FT   VARIANT         768
FT                   /note="P -> R (in GSD2; infantile form)"
FT                   /evidence="ECO:0000269|PubMed:9521422"
FT                   /id="VAR_004312"
FT   VARIANT         780
FT                   /note="V -> I (in dbSNP:rs1126690)"
FT                   /evidence="ECO:0000269|PubMed:2111708,
FT                   ECO:0000269|PubMed:2268276, ECO:0000269|PubMed:25681614,
FT                   ECO:0000269|PubMed:3049072, ECO:0000269|PubMed:7717400,
FT                   ECO:0000269|Ref.5"
FT                   /id="VAR_004313"
FT   VARIANT         816
FT                   /note="V -> I (in dbSNP:rs1800314)"
FT                   /evidence="ECO:0000269|PubMed:1684505,
FT                   ECO:0000269|PubMed:25681614, ECO:0000269|PubMed:8094613,
FT                   ECO:0000269|PubMed:8486380"
FT                   /id="VAR_004314"
FT   VARIANT         819
FT                   /note="R -> P (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068633"
FT   VARIANT         880
FT                   /note="A -> D (in GSD2; infantile form; severe; loss of
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:14695532"
FT                   /id="VAR_018097"
FT   VARIANT         901
FT                   /note="L -> Q (in GSD2; infantile form; severe)"
FT                   /evidence="ECO:0000269|PubMed:15145338"
FT                   /id="VAR_029039"
FT   VARIANT         903
FT                   /note="Missing (in GSD2; infantile form; severe; loss of
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:7717400"
FT                   /id="VAR_004315"
FT   VARIANT         913
FT                   /note="P -> R (in GSD2; dbSNP:rs1480070037)"
FT                   /evidence="ECO:0000269|PubMed:22676651"
FT                   /id="VAR_070020"
FT   VARIANT         916
FT                   /note="V -> F (in GSD2; dbSNP:rs1221948995)"
FT                   /evidence="ECO:0000269|PubMed:22644586"
FT                   /id="VAR_068634"
FT   VARIANT         925
FT                   /note="N -> NGVPVSN (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:10206684"
FT                   /id="VAR_004316"
FT   VARIANT         927
FT                   /note="T -> I (loss of glycosylation site;
FT                   dbSNP:rs1800315)"
FT                   /evidence="ECO:0000269|PubMed:1684505,
FT                   ECO:0000269|PubMed:8094613, ECO:0000269|PubMed:8486380"
FT                   /id="VAR_004317"
FT   VARIANT         935
FT                   /note="L -> P (in GSD2)"
FT                   /evidence="ECO:0000269|PubMed:18425781"
FT                   /id="VAR_068635"
FT   VARIANT         949
FT                   /note="V -> D (in GSD2; dbSNP:rs1245412108)"
FT                   /id="VAR_004318"
FT   MUTAGEN         516
FT                   /note="W->R: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:1856189"
FT   MUTAGEN         518
FT                   /note="D->G,N,E: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:1856189"
FT   HELIX           80..82
FT                   /evidence="ECO:0007829|PDB:5KZW"
FT   HELIX           86..88
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          94..96
FT                   /evidence="ECO:0007829|PDB:5NN3"
FT   HELIX           100..105
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          126..128
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          137..143
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          145..153
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          159..163
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          166..173
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          175..184
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          208..214
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   TURN            215..218
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          219..224
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   TURN            225..227
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          230..233
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           234..236
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          240..242
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          245..251
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          253..255
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          257..259
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          272..278
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          297..301
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          307..312
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          318..323
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   TURN            324..326
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          327..335
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          337..342
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           347..358
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           366..369
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           381..393
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          399..403
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           405..407
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   TURN            420..423
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           424..433
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          437..442
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           456..464
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          473..475
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          477..480
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          483..486
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           493..509
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          514..517
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   TURN            520..522
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          525..528
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   TURN            537..539
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   TURN            552..555
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          564..567
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           568..571
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           572..574
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           575..591
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          597..601
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           606..608
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          611..613
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          618..620
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           621..636
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          641..643
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          649..651
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           655..665
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          668..670
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          677..679
FT                   /evidence="ECO:0007829|PDB:5NN8"
FT   HELIX           684..686
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           689..704
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           706..719
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          723..725
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           727..730
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           735..737
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          742..746
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   TURN            747..749
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          750..753
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          761..767
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          769..774
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           775..777
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          796..808
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          815..819
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          822..827
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           833..836
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          841..846
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          853..859
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           867..870
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          874..881
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          884..891
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   HELIX           894..896
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          900..907
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          916..918
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          926..929
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   TURN            930..933
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          934..942
FT                   /evidence="ECO:0007829|PDB:5NN4"
FT   STRAND          948..951
FT                   /evidence="ECO:0007829|PDB:5NN4"
SQ   SEQUENCE   952 AA;  105324 MW;  6E2717BF7201F469 CRC64;
     MGVRHPPCSH RLLAVCALVS LATAALLGHI LLHDFLLVPR ELSGSSPVLE ETHPAHQQGA
     SRPGPRDAQA HPGRPRAVPT QCDVPPNSRF DCAPDKAITQ EQCEARGCCY IPAKQGLQGA
     QMGQPWCFFP PSYPSYKLEN LSSSEMGYTA TLTRTTPTFF PKDILTLRLD VMMETENRLH
     FTIKDPANRR YEVPLETPHV HSRAPSPLYS VEFSEEPFGV IVRRQLDGRV LLNTTVAPLF
     FADQFLQLST SLPSQYITGL AEHLSPLMLS TSWTRITLWN RDLAPTPGAN LYGSHPFYLA
     LEDGGSAHGV FLLNSNAMDV VLQPSPALSW RSTGGILDVY IFLGPEPKSV VQQYLDVVGY
     PFMPPYWGLG FHLCRWGYSS TAITRQVVEN MTRAHFPLDV QWNDLDYMDS RRDFTFNKDG
     FRDFPAMVQE LHQGGRRYMM IVDPAISSSG PAGSYRPYDE GLRRGVFITN ETGQPLIGKV
     WPGSTAFPDF TNPTALAWWE DMVAEFHDQV PFDGMWIDMN EPSNFIRGSE DGCPNNELEN
     PPYVPGVVGG TLQAATICAS SHQFLSTHYN LHNLYGLTEA IASHRALVKA RGTRPFVISR
     STFAGHGRYA GHWTGDVWSS WEQLASSVPE ILQFNLLGVP LVGADVCGFL GNTSEELCVR
     WTQLGAFYPF MRNHNSLLSL PQEPYSFSEP AQQAMRKALT LRYALLPHLY TLFHQAHVAG
     ETVARPLFLE FPKDSSTWTV DHQLLWGEAL LITPVLQAGK AEVTGYFPLG TWYDLQTVPV
     EALGSLPPPP AAPREPAIHS EGQWVTLPAP LDTINVHLRA GYIIPLQGPG LTTTESRQQP
     MALAVALTKG GEARGELFWD DGESLEVLER GAYTQVIFLA RNNTIVNELV RVTSEGAGLQ
     LQKVTVLGVA TAPQQVLSNG VPVSNFTYSP DTKVLDICVS LLMGEQFLVS WC
//
